Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xin-Rong Yang

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
The Oncologist|November 11, 2008
Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resectionGuo-Huan Yang, Jia Fan, Yang Xu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Postoperative circulating tumor cells predict the benefits of tyrosine kinase inhibitor for hepatocellular carcinoma after transplantationDe-Zhen Guo, Shi-Yu Zhang, Man Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2011
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinomaYang Xu, Venugopal Chenna, Chaoxin Hu, et al.
Frontiers in Immunology|March 13, 2023
Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapyDe-Zhen Guo, Shi-Yu Zhang, San-Yuan Dong, et al.
Annals of Translational Medicine|November 17, 2022
Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteriaDe-Zhen Guo, Jian-Wen Cheng, Jia-Yan Yan, et al.
The Oncologist|March 27, 2019
Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching AnalysisZi-Jun Gong, Jian-Wen Cheng, Pin-Ting Gao, et al.
Journal of Cellular and Molecular Medicine|February 16, 2022
Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activityLi-Hua Lyu, Chun-Yan Zhang, Wen-Jing Yang, et al.
Frontiers in Oncology|March 13, 2023
Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapyDe-Zhen Guo, Shi-Yu Zhang, San-Yuan Dong, et al.
Clinical and Translational Medicine|February 26, 2021
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergisticallyXin Zhang, Bo Hu, Yun-Fan Sun, et al.
Frontiers in Oncology|July 30, 2021
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized MedicineYang Gao, Rong Zhou, Jun-Feng Huang, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
The Oncologist|November 11, 2008
Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resectionGuo-Huan Yang, Jia Fan, Yang Xu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Postoperative circulating tumor cells predict the benefits of tyrosine kinase inhibitor for hepatocellular carcinoma after transplantationDe-Zhen Guo, Shi-Yu Zhang, Man Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2011
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinomaYang Xu, Venugopal Chenna, Chaoxin Hu, et al.
Frontiers in Immunology|March 13, 2023
Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapyDe-Zhen Guo, Shi-Yu Zhang, San-Yuan Dong, et al.
Annals of Translational Medicine|November 17, 2022
Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteriaDe-Zhen Guo, Jian-Wen Cheng, Jia-Yan Yan, et al.
The Oncologist|March 27, 2019
Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching AnalysisZi-Jun Gong, Jian-Wen Cheng, Pin-Ting Gao, et al.
Journal of Cellular and Molecular Medicine|February 16, 2022
Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activityLi-Hua Lyu, Chun-Yan Zhang, Wen-Jing Yang, et al.
Frontiers in Oncology|March 13, 2023
Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapyDe-Zhen Guo, Shi-Yu Zhang, San-Yuan Dong, et al.
Clinical and Translational Medicine|February 26, 2021
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergisticallyXin Zhang, Bo Hu, Yun-Fan Sun, et al.
Frontiers in Oncology|July 30, 2021
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized MedicineYang Gao, Rong Zhou, Jun-Feng Huang, et al.
Pageof 12